drugset / Trial / NCT05031546
Intermediate-Size Patient Population Expanded Access Program for Intravenous Difelikefalin
Summary
This is an intermediate-size patient population expanded access protocol for the use of intravenous (IV) difelikefalin for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult patients undergoing hemodialysis.
Timeline
- Start
- —
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Difelikefalin | Protein / enzyme biologic | 0.5 ug/kg | Intravenous |
Indications
No indication recorded.